| Run Xue, MD | |
|
12917 Se 38th St, Ste 100, Bellevue, WA 98006-1349 | |
| (425) 641-4000 | |
| (206) 320-5840 |
| Full Name | Run Xue |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 36 Years |
| Location | 12917 Se 38th St, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265594162 | NPI | - | NPPES |
| 0127087 | Other | WA | LABOR AND INDUSTRIES |
| 8229635 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD00036195 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Issaquah | Issaquah, WA | Hospital |
| Overlake Hospital Medical Center | Bellevue, WA | Hospital |
| Swedish Medical Center | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Swedish Health Services | 9537072814 | 323 |
News Archive
New research out of the University of Toronto Scarborough - published in this month's edition of Acta Psychologica - shows that using your inner voice plays an important role in controlling impulsive behaviour.
For up-to-date information about lung cancer, you can contact the Thomas G. Labrecque Foundation. The foundation was founded in 2002 by the Labrecque family in honor of Tom Labrecque, former chairman of the Chase Manhattan Bank. Mr. Labrecque, a non-smoker, died of lung cancer.
April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.
Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.
› Verified 7 days ago
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831139724 PECOS PAC ID: 9537072814 Enrollment ID: O20031112000189 |
News Archive
New research out of the University of Toronto Scarborough - published in this month's edition of Acta Psychologica - shows that using your inner voice plays an important role in controlling impulsive behaviour.
For up-to-date information about lung cancer, you can contact the Thomas G. Labrecque Foundation. The foundation was founded in 2002 by the Labrecque family in honor of Tom Labrecque, former chairman of the Chase Manhattan Bank. Mr. Labrecque, a non-smoker, died of lung cancer.
April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.
Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.
› Verified 7 days ago
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689612954 PECOS PAC ID: 0244138196 Enrollment ID: O20031230000187 |
News Archive
New research out of the University of Toronto Scarborough - published in this month's edition of Acta Psychologica - shows that using your inner voice plays an important role in controlling impulsive behaviour.
For up-to-date information about lung cancer, you can contact the Thomas G. Labrecque Foundation. The foundation was founded in 2002 by the Labrecque family in honor of Tom Labrecque, former chairman of the Chase Manhattan Bank. Mr. Labrecque, a non-smoker, died of lung cancer.
April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.
Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Run Xue, MD Po Box 84026, Seattle, WA 98124-8426 Ph: (425) 641-4000 | Run Xue, MD 12917 Se 38th St, Ste 100, Bellevue, WA 98006-1349 Ph: (425) 641-4000 |
News Archive
New research out of the University of Toronto Scarborough - published in this month's edition of Acta Psychologica - shows that using your inner voice plays an important role in controlling impulsive behaviour.
For up-to-date information about lung cancer, you can contact the Thomas G. Labrecque Foundation. The foundation was founded in 2002 by the Labrecque family in honor of Tom Labrecque, former chairman of the Chase Manhattan Bank. Mr. Labrecque, a non-smoker, died of lung cancer.
April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.
Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.
› Verified 7 days ago
Joseph W Doucette, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 600, Bellevue, WA 98004 Phone: 425-454-2656 Fax: 425-990-5261 | |
Roanne R E Selinger, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 | |
Patsy C Lazarous, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 Fax: 844-620-1839 | |
Dr. Patricia Martin, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1407 116th Ave Ne, Suite 200, Bellevue, WA 98004 Phone: 425-454-5046 Fax: 425-990-5261 | |
Dr. Rahil Barketali Roopani, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1800 116th Ave Ne Ste 102, Bellevue, WA 98004 Phone: 425-947-9485 Fax: 425-977-9034 | |
David C Morton, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 110a, Bellevue, WA 98004 Phone: 425-289-3100 Fax: 425-289-3103 | |
Shie-pon Tzung, MD PHD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 |